Margaret J Livingstone1, Cornelius B Groenewald1, Jennifer A Rabbitts1, Tonya M Palermo1,2,3. 1. Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA, USA. 2. Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA. 3. Department of Psychiatry, University of Washington School of Medicine, Seattle, WA, USA.
Abstract
BACKGROUND: Concerns regarding the safety of codeine have been raised. Cases of life-threatening respiratory depression and death in children have been attributed to codeine's polymorphic metabolic pathway. International health agencies recommend restricted use of codeine in children. Despite these recommendations, the epidemiology of codeine use among children remains unknown. AIMS: Our objective was to examine patterns of codeine use in the US among children. METHODS: A cross-sectional analysis of children of age 0-17 years from 1996 to 2013 in the US was performed. Data were extracted from MEPS, a nationally representative set of health care surveys. Prevalence rates of codeine use between 1996 and 2013 were examined. Multivariable logistic regression examined relationships between codeine use and patient demographics. RESULTS: Codeine use remained largely unchanged from 1996 to 2013 (1.08 vs 1.03 million children, respectively). Odds of codeine use was higher in ages 12-17 (OR, 1.40; [1.21-1.61]), outside of the Northeastern US, and among those with poor physical health status (OR, 3.29 [1.79-6.03]). Codeine use was lower in children whose ethnicity was not white and those uninsured (OR, 0.47 [0.34-0.63]). Codeine was most frequently prescribed by emergency physicians (18%) and dentists (14%). The most common condition associated with codeine use was trauma-related pain. CONCLUSIONS: Pediatric codeine use has declined since 1996; however, more than 1 million children still used codeine in 2013. Health care providers must be made aware of guidelines advising against the use of codeine in children. Codeine is potentially hazardous and safer alternatives to treat children's pain are available.
BACKGROUND: Concerns regarding the safety of codeine have been raised. Cases of life-threatening respiratory depression and death in children have been attributed to codeine's polymorphic metabolic pathway. International health agencies recommend restricted use of codeine in children. Despite these recommendations, the epidemiology of codeine use among children remains unknown. AIMS: Our objective was to examine patterns of codeine use in the US among children. METHODS: A cross-sectional analysis of children of age 0-17 years from 1996 to 2013 in the US was performed. Data were extracted from MEPS, a nationally representative set of health care surveys. Prevalence rates of codeine use between 1996 and 2013 were examined. Multivariable logistic regression examined relationships between codeine use and patient demographics. RESULTS:Codeine use remained largely unchanged from 1996 to 2013 (1.08 vs 1.03 million children, respectively). Odds of codeine use was higher in ages 12-17 (OR, 1.40; [1.21-1.61]), outside of the Northeastern US, and among those with poor physical health status (OR, 3.29 [1.79-6.03]). Codeine use was lower in children whose ethnicity was not white and those uninsured (OR, 0.47 [0.34-0.63]). Codeine was most frequently prescribed by emergency physicians (18%) and dentists (14%). The most common condition associated with codeine use was trauma-related pain. CONCLUSIONS: Pediatric codeine use has declined since 1996; however, more than 1 million children still used codeine in 2013. Health care providers must be made aware of guidelines advising against the use of codeine in children. Codeine is potentially hazardous and safer alternatives to treat children's pain are available.
Authors: Catherine Ciszkowski; Parvaz Madadi; Michael S Phillips; Albert E Lauwers; Gideon Koren Journal: N Engl J Med Date: 2009-08-20 Impact factor: 91.245
Authors: Sunitha V Kaiser; Renee Asteria-Penaloza; Eric Vittinghoff; Glenn Rosenbluth; Michael D Cabana; Naomi S Bardach Journal: Pediatrics Date: 2014-04-21 Impact factor: 7.124
Authors: Parvaz Madadi; Doris Hildebrandt; Inna Y Gong; Ute I Schwarz; Catherine Ciszkowski; Colin J D Ross; Johanna Sistonen; Bruce C Carleton; Michael R Hayden; Albert E Lauwers; Gideon Koren Journal: Pediatrics Date: 2010-09-13 Impact factor: 7.124
Authors: Lauren E Kelly; Michael Rieder; John van den Anker; Becky Malkin; Colin Ross; Michael N Neely; Bruce Carleton; Michael R Hayden; Parvaz Madadi; Gideon Koren Journal: Pediatrics Date: 2012-04-09 Impact factor: 7.124
Authors: Roseann S Gammal; Kelly E Caudle; Charles T Quinn; Winfred C Wang; Andrea Gaedigk; Cynthia A Prows; Cyrine E Haidar; Annette K Taylor; Teri E Klein; Katrin Sangkuhl; Jane S Hankins; Kristine R Crews Journal: Clin Pharmacol Ther Date: 2018-11-22 Impact factor: 6.875
Authors: Cecilia P Chung; Stephen Todd Callahan; William O Cooper; William D Dupont; Katherine T Murray; Andrew D Franklin; Kathi Hall; Judith A Dudley; Charles Michael Stein; Wayne A Ray Journal: Pharmacoepidemiol Drug Saf Date: 2019-08-16 Impact factor: 2.890